An independent publication in Nature: Scientific Reports cites using fresh leukopaks sourced from HemaCare in their T cell cryopreservation study. The authors, who work at the Cell and Gene Therapy Catapult in London, are studying the impact of cooling and thawing rates on cryopreserved human peripheral blood-derived T cells. In order for the emerging cell and gene therapy industry to effectively ship and store cell-based therapies to global markets, it will be necessary to cryopreserve cell therapy starting materials, as well as the final therapeutic products. To retain peak cellular function, and therefore therapeutic efficacy upon patient administration, it is necessary to understand how to optimize the cryopreservation process.
Scientists at antibody engineering company Xencor in Monrovia, CA have just published a research paper that cites using HemaCare sourced leukopaks in the development of their new antibody platform.
Monoclonal antibody therapy has become central to the treatment of many different diseases, including autoimmune disorders, asthma and cancer. Yet in spite of this success, many disease targets have yet to be effectively addressed. Monoclonal antibodies have trouble binding to antigens that are weakly expressed, which results in a need for higher dosing concentrations. High treatment dosages, in turn, can lead to toxicity effects. Monoclonals are also limited in that they can only block one target at a time, leaving parallel disease pathways open that can lead to treatment resistance.
Combining various treatment approaches is seen as a viable, more powerful means to achieve HIV cure states.
From the time that HIV-related illness and death was first realized in the 1980s until now, efforts to fully understand HIV infection and pathogenesis have been ongoing along with massive research efforts to discover a cure or means to control the spread of the virus. The newest antiviral therapies have made an extraordinary impact on the control of disease progression; however, these do not cure HIV infection and the viral activity returns shortly after antiviral dosing stops. Approaches to achieve HIV immunity are heavily studied, including developing means to provide HIV immunity in T cells and conferring HIV-resistance via gene editing. However, combining various approaches is seen as a viable, more powerful means to achieve HIV control or even a cure.
Last week, HemaCare published an article in Technology Networks discussing how optimal apheresis and collection methods give cell therapies a leading edge1
Cell therapy is a unique field because the “products” are derived from living human cells and where each donor is different, variability is inevitable. Quality precursor material gives cell therapy products their best start. Variable or low-quality starting material introduces a need for complex separation strategies or repeated manufacturing runs, leading to higher costs and resource requirements.1 To ensure the process utilizes the right resources, scientists must adopt optimal apheresis instrumentation and collection methods as one of the most important steps.
Many people have donated blood in their lifetime. This blood is not only used for transfusions, but to provide blood components to treat a number of diseases and to conduct research geared to develop new diagnostic and treatment strategies. To obtain specific blood components, the technique of apheresis is used. This procedure is the means to separate blood into its various components so that the desired one is removed. Then, the rest of the components are placed back into the donor’s circulation.